Weber, B.Y.; Brenner, G.B.; Kiss, B.; Gergely, T.G.; Sayour, N.V.; Tian, H.; Makkos, A.; Görbe, A.; Ferdinandy, P.; Giricz, Z.
Rosiglitazone Does Not Show Major Hidden Cardiotoxicity in Models of Ischemia/Reperfusion but Abolishes Ischemic Preconditioning-Induced Antiarrhythmic Effects in Rats In Vivo. Pharmaceuticals 2022, 15, 1055.
https://doi.org/10.3390/ph15091055
AMA Style
Weber BY, Brenner GB, Kiss B, Gergely TG, Sayour NV, Tian H, Makkos A, Görbe A, Ferdinandy P, Giricz Z.
Rosiglitazone Does Not Show Major Hidden Cardiotoxicity in Models of Ischemia/Reperfusion but Abolishes Ischemic Preconditioning-Induced Antiarrhythmic Effects in Rats In Vivo. Pharmaceuticals. 2022; 15(9):1055.
https://doi.org/10.3390/ph15091055
Chicago/Turabian Style
Weber, Bennet Y., Gábor B. Brenner, Bernadett Kiss, Tamás G. Gergely, Nabil V. Sayour, Huimin Tian, András Makkos, Anikó Görbe, Péter Ferdinandy, and Zoltán Giricz.
2022. "Rosiglitazone Does Not Show Major Hidden Cardiotoxicity in Models of Ischemia/Reperfusion but Abolishes Ischemic Preconditioning-Induced Antiarrhythmic Effects in Rats In Vivo" Pharmaceuticals 15, no. 9: 1055.
https://doi.org/10.3390/ph15091055
APA Style
Weber, B. Y., Brenner, G. B., Kiss, B., Gergely, T. G., Sayour, N. V., Tian, H., Makkos, A., Görbe, A., Ferdinandy, P., & Giricz, Z.
(2022). Rosiglitazone Does Not Show Major Hidden Cardiotoxicity in Models of Ischemia/Reperfusion but Abolishes Ischemic Preconditioning-Induced Antiarrhythmic Effects in Rats In Vivo. Pharmaceuticals, 15(9), 1055.
https://doi.org/10.3390/ph15091055